Exclusive special offer and discount title banner vector image

CHINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET FORECAST 2024-2032

SCOPE OF THE REPORT

China Antibody Drug Conjugates Contract Manufacturing Market by Phase (Clinical Phase, Commercial Phase) Market by Linker (Cleavable Linkers, Non-cleavable Linkers) Market by Condition (Myeloma, Lymphoma, Breast Cancer, Other Conditions)


MARKET OVERVIEW

The China antibody drug conjugates contract manufacturing market is anticipated to progress at a CAGR of 12.34% over the forecast period of 2024-2032. It is positioned to reach a revenue of $4361.08 million by 2032

The China antibody drug conjugates contract manufacturing market is experiencing significant growth, driven by several key factors. One of these factors is the surging global incidence of cancer, which has created a growing demand for effective treatment options such as antibody drug conjugates. This demand has led to increased investment and focus on developing ADCs, making China a strategic location for contract manufacturing in this field.

Another crucial driver is the advancements in drug conjugation technologies. These technological developments have improved the efficiency and effectiveness of ADCs, making them more targeted and reducing potential side effects. This progress has fueled the demand for contract manufacturing services from companies looking to capitalize on these innovations.

China Antibody Drug Conjugates Contract Manufacturing Market

To Know More About This Report, Request a Free Sample Copy

Furthermore, the increasing collaboration between key contract manufacturers (CMOs) in China and global pharmaceutical companies has contributed to the market’s growth. These collaborations bring together expertise in drug development, manufacturing capabilities, and regulatory knowledge, enabling the efficient production and delivery of high-quality ADCs to meet the rising demand.

However, navigating the complex regulatory requirements remains a challenge for players in the China ADC contract manufacturing industry. The stringent regulatory landscape in the China antibody drug conjugates contract manufacturing market necessitates compliance with quality standards and approvals. This requires careful planning and execution to ensure regulatory compliance while also maintaining production efficiency and meeting the demands of the market.

The China antibody drug conjugates contract manufacturing market segmentation includes the market by phase, linker, and condition. The linker segment is further divided into cleavable linkers and non-cleavable linkers. Cleavable linkers are designed to release the drug payload inside the targeted cancer cells, often in response to specific conditions or stimuli within the cell environment. This targeted release mechanism enhances the efficacy of the ADCs by concentrating the drug’s action at the tumor site while minimizing off-target effects.

On the other hand, non-cleavable linkers are designed to remain stable within the bloodstream and the extracellular environment until they are taken up by cancer cells. Once inside the cells, the ADCs undergo internalization and degradation, releasing the drug payload directly into the cancer cells. This mechanism provides a different approach to targeting cancer cells and delivering therapeutic agents, offering options for diverse treatment strategies in oncology.

Furthermore, advancements in linker technologies continue to drive innovation in the China ADC contract manufacturing market. New linker designs aim to improve the stability, specificity, and controllability of drug release, enhancing the overall therapeutic efficacy and safety profiles of ADCs. The ongoing evolution in linker technology highlights the dynamic nature of the ADC landscape. This emphasizes the importance of adaptable manufacturing capabilities to meet evolving market demands and clinical requirements.

Some of the leading players in the China antibody drug conjugates contract manufacturing market include WuXi Biologics, AbbVie Inc (AbbVie Contract Manufacturing), Merck KGaA, etc. 

WuXi Biologics is a leading global biologics contract research and manufacturing organization, providing comprehensive solutions for biologic discovery, development, and manufacturing. They offer a wide range of services, including bioprocess development, biosafety, GMP manufacturing, cell line development, and analytical characterization. WuXi Biologics, headquartered in Wuxi, China, has a global presence spanning North America, Europe, and Asia-Pacific. The company specializes in antibody and protein production, vaccine development, and continuous manufacturing.

REPORT SYNOPSIS

REPORT SCOPEDETAILS
Market Forecast Years2024-2032
Base Year2023
Market Historical Years2018-2022
Forecast Units

Revenue ($ Million)

Segments Analyzed
Phase, Linker, and Condition
Countries AnalyzedChina
Companies AnalyzedAbbVie Inc (AbbVie Contract Manufacturing), Merck KGaA, WuXi Biologics, Samsung Biologics, Lonza Group
TABLE OF CONTENTS
  1. RESEARCH SCOPE & METHODOLOGY
    1. STUDY OBJECTIVES
    2. METHODOLOGY
    3. ASSUMPTIONS & LIMITATIONS
  2. EXECUTIVE SUMMARY
    1. MARKET SIZE & ESTIMATES
    2. COUNTRY SNAPSHOT
    3. COUNTRY ANALYSIS
    4. SCOPE OF STUDY
    5. CRISIS SCENARIO ANALYSIS
    6. MAJOR MARKET FINDINGS
      1. INCREASING COLLABORATION BETWEEN KEY CONTRACT MANUFACTURERS (CMOS)
      2. CHALLENGES IN NAVIGATING COMPLEX REGULATORY REQUIREMENTS
  3. MARKET DYNAMICS
    1. KEY DRIVERS
      1. RISING DEMAND FOR TARGETED THERAPIES
      2. GROWING INCLINATION TOWARDS CONTRACT MANUFACTURING COMPANIES AS AN ECONOMICAL CHOICE
      3. SURGING GLOBAL CANCER INCIDENCE
      4. ADVANCEMENTS IN DRUG CONJUGATION TECHNOLOGIES
    2. KEY RESTRAINTS
      1. HIGH COST OF ADC (ANTIBODY DRUG CONJUGATES) DEVELOPMENT AND MANUFACTURING
      2. INCREASING COMPETITION FROM BIOSIMILAR ADC (ANTIBODY DRUG CONJUGATES) AND GENERIC DRUGS
      3. STRINGENT REGULATORY REQUIREMENTS
  4. KEY ANALYTICS
    1. KEY MARKET TRENDS
      1. RISING DEMAND FOR ADCS
      2. GROWING FOCUS ON ADC QUALITY AND REGULATORY COMPLIANCE
    2. PESTLE ANALYSIS
      1. POLITICAL
      2. ECONOMICAL
      3. SOCIAL
      4. TECHNOLOGICAL
      5. LEGAL
      6. ENVIRONMENTAL
    3. PORTER’S FIVE FORCES ANALYSIS
      1. BUYERS POWER
      2. SUPPLIERS POWER
      3. SUBSTITUTION
      4. NEW ENTRANTS
      5. INDUSTRY RIVALRY
    4. GROWTH PROSPECT MAPPING 
      1. GROWTH PROSPECT MAPPING FOR CHINA
    5. MARKET CONCENTRATION ANALYSIS
    6. KEY BUYING CRITERIA
      1. EXPERTISE AND EXPERIENCE
      2. MANUFACTURING CAPACITY
      3. REGULATORY COMPLIANCE
      4. QUALITY CONTROL
      5. COST
    7. REGULATORY FRAMEWORK
  5. MARKET BY PHASE
    1. CLINICAL PHASE
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
    2. COMMERCIAL PHASE
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
  6. MARKET BY LINKER
    1. CLEAVABLE LINKERS
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
    2. NON-CLEAVABLE LINKERS
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
  7. MARKET BY CONDITION
    1. MYELOMA
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
    2. LYMPHOMA
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
    3. BREAST CANCER
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
    4. OTHER CONDITIONS
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
  8. COMPETITIVE LANDSCAPE
    1. KEY STRATEGIC DEVELOPMENTS
      1. MERGERS & ACQUISITIONS
      2. PRODUCT LAUNCHES & DEVELOPMENTS
      3. PARTNERSHIPS & AGREEMENTS
    2. COMPANY PROFILES
      1. ABBVIE INC (ABBVIE CONTRACT MANUFACTURING)
        1. COMPANY OVERVIEW
        2. SERVICES LIST
        3. STRENGTHS & CHALLENGES
      2. LONZA GROUP
        1. COMPANY OVERVIEW
        2. SERVICES LIST
        3. STRENGTHS & CHALLENGES
      3. MERCK KGAA
        1. COMPANY OVERVIEW
        2. SERVICES LIST
        3. STRENGTHS & CHALLENGES
      4. SAMSUNG BIOLOGICS
        1. COMPANY OVERVIEW
        2. SERVICES LIST
        3. STRENGTHS & CHALLENGES
      5. WUXI BIOLOGICS
        1. COMPANY OVERVIEW
        2. SERVICES LIST
        3. STRENGTHS & CHALLENGES

LIST OF TABLES

TABLE 1: MARKET SNAPSHOT – ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING

TABLE 2: REGULATORY FRAMEWORK

TABLE 3: CHINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY PHASE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 4: CHINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY PHASE, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 5: CHINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY LINKER, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 6: CHINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY LINKER, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 7: CHINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY CONDITION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 8: CHINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY CONDITION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 9: LIST OF MERGERS & ACQUISITIONS

TABLE 10: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS

TABLE 11: LIST OF PARTNERSHIPS & AGREEMENTS

 

LIST OF FIGURES

FIGURE 1: KEY MARKET TRENDS

FIGURE 2: PORTER’S FIVE FORCES ANALYSIS

FIGURE 3: GROWTH PROSPECT MAPPING FOR CHINA

FIGURE 4: MARKET CONCENTRATION ANALYSIS

FIGURE 5: KEY BUYING CRITERIA

FIGURE 6: CHINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, GROWTH POTENTIAL, BY PHASE, IN 2023

FIGURE 7: CHINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY CLINICAL PHASE, 2024-2032 (IN $ MILLION)

FIGURE 8: CHINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY COMMERCIAL PHASE, 2024-2032 (IN $ MILLION)

FIGURE 9: CHINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, GROWTH POTENTIAL, BY LINKER, IN 2023

FIGURE 10: CHINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY CLEAVABLE LINKERS, 2024-2032 (IN $ MILLION)

FIGURE 11: CHINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY NON-CLEAVABLE LINKERS, 2024-2032 (IN $ MILLION)

FIGURE 12: CHINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, GROWTH POTENTIAL, BY CONDITION, IN 2023

FIGURE 13: CHINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY MYELOMA, 2024-2032 (IN $ MILLION)

FIGURE 14: CHINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY LYMPHOMA, 2024-2032 (IN $ MILLION)

FIGURE 15: CHINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY BREAST CANCER, 2024-2032 (IN $ MILLION)

FIGURE 16: CHINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY OTHER CONDITIONS, 2024-2032 (IN $ MILLION)

FAQ’s